My company develops and produces a biologic. Recently, regulatory authorities asked us to document how efficiently downstream purification reduces the levels of specific enzymes that are added during process development.
How can I measure and follow the levels of enzymes and other proteins added during manufacturing? Is there a reproducible method available, which detects these residuals down to low ppm levels?
Yes, there is a terrific method for residual protein detection, with detection limits down to low ppm levels. It can track and quantify the residuals through all purification steps, and eventually in the final biopharmaceutical product.
However, let’s first have a look at process-related residual proteins often applied in process development – and why they increasingly concern FDA/EMA.
The different types of process-related residual proteins
During the development and production of biologics, such as monoclonal antibodies, antibody-drug-conjugates, therapeutic proteins, gene therapy products and vaccines, process-related impurities follow along with the product.
Typically, we divide impurities into three subtypes that depend on origin:
- Cell substrate-derived / product-derived (e.g. host cell proteins, host cell DNA)
- Cell culture-derived (e.g. antibiotics, IPTG, DTT, growth factors)
- Downstream derived / process-derived residuals (e.g. enzymes, buffer components)
Note that the third subtype often includes the cell-culture-derived impurities. We also call the third subtype process-related residuals.
This type consists of agents used to express and purify biological protein products. Common process-related residuals include: Benzonase nuclease, enzymes for site-specific PEGylation, aminopeptidase, Protein A, Tris, carriers, ligands, Tween/Polysorbate, DCA, TCEP, heavy metals, solvents, Triton-X, antifoaming agents, PEI, TFA/Acetate, Imidazole, etc.
Why are residuals a concern?
Investigating the levels of residuals is crucial, especially in the final product sample. Because, like host cell proteins, residuals can influence the stability and efficacy of the active ingredient. It may even pose a risk to the patient’s safety [1-3].
Since more sensitive analytical methods now exist for residuals analysis, FDA and EMA seem more and more interested in data that map out the purification process’ efficiency [1-3].
How to fully document residuals clearance with mass spectrometry
FDA/EMA request an increasing number of biopharmaceutical companies for documentation of residual protein clearance before a biologic can move forward in late-stage clinical trials [1-3].
The problem, however, is that older methodologies like ELISA and HPLC are restricted by low antibody-specificity and too-high limit of quantification, respectively. Since the residuals in samples are present in only low-ppm levels, you need a highly sensitive and reproducible approach to get a detailed overview of the residual protein clearance [4, 5].
Luckily, SWATH LC-MS offers exactly that. It fragments all peptides instead of only a group of selected precursors, by using Data Independent Acquisition (DIA). In SWATH LC-MS, the defined mass range is divided into small mass windows for MS/MS fragmentation of the peptides. Afterwards, comparing the acquired MS data to an ion library of known peptides will identify the proteins .
The advantages of SWATH LC-MS for residuals analysis include:
- Highly reproducible identification and quantification, due to the use of DIA mode
- Interference, from high amount of drug substance on the signal of low abundant residuals, is kept low by using small mass windows for MS/MS fragmentation
- Specific residuals can be followed throughout the entire process development. You can also use it to compare batches and for quality control after upscaling of batches
- A high throughput of samples makes it possible to quickly assess many individual samples from various steps in the purification
- A high sensitivity makes it possible to quantify low ppm levels
With these advantages, SWATH LC-MS is ideal for analysis of process-related residuals used in development of biologics .
Need more information?
 U.S. Department of Health and Human Services – Food and Drug Administration: “Immunogenicity Testing of Therapeutic Protein Products — Developing and Validating Assays for Anti-Drug Antibody Detection: Guidance for Industry”, 2019
 U.S. Department of Health and Human Services – Food and Drug Administration: “Q3C Impurities – Residual Solvents: Guidance for Industry”, 1997
 European Medicines Agency: “Guideline on Immunogenicity assessment of therapeutic proteins”, 2017
 Zhu-Shimoni et al: “Host Cell Protein Testing by ELISAs and the Use of Orthogonal Methods”, Biotechnology and Bioengineering, 2014
 Bracewell et al: “The Future of Host Cell Protein (HCP) Identification During Process Development and Manufacturing Linked to a Risk-Based Management for Their Control” , Biotechnology and Bioengineering, 2015
 Heissel et al: “Evaluation of spectral libraries and sample preparation for DIA-LC-MS analysis of host cell proteins: A case study of a bacterially expressed recombinant biopharmaceutical protein”, Protein Expression and Purification, 2018